🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed and Refractory

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tab… Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778Phase 231 sites📍 Phoenix📍 San Francisco📍 Jacksonville CellCentric Ltd. · Tests: Inobrodib, Pomalidomide, Dexamethasone A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites📍 Coral Gables📍 Deerfield Beach📍 Miami University of Miami · Tests: Selinexor, Venetoclax, Dexamethasone Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases NCT05827835Phase 1, Phase 21 site📍 Hangzhou Zhejiang University · Tests: CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site📍 Scottsdale Mayo Clinic · Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site📍 Wuhan Tongji Hospital · Tests: JY231 Injection Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: cladribine, cytarabine,venetoclax Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma NCT07725380Phase 1, Phase 24 sites📍 Tampa📍 St Louis📍 The Bronx H. Lee Moffitt Cancer Center and Research Institute · Tests: Domatinostat, Sirolimus A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT07044050Phase 11 site📍 Montpellier Emercell SAS · Tests: allogenic natural killer cells Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease NCT05907759Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Daratumumab SC Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL NCT07074470NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASC… A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma NCT06563505Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Mosunetuzumab, Zanubrutinib Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707Phase 11 site📍 Hangzhou Zhejiang University · Tests: KSV01 Injection A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy